Comparing WTP values of different types of QALY gain elicited from the general public

Health Economics (United Kingdom)

Volumn 24, Issue 3, 2015, Pages 280-293

  Pennington, Mark ^a,g   Baker, Rachel ^b   Brouwer, Werner ^c   Mason, Helen ^b   Hansen, Dorte Gyrd ^d,e   Robinson, Angela ^f,i   Donaldson, Cam ^b   Bell, Sue ^g   Jones Lee, Michael ^g   Wildman, John ^g   Lancsar, Emily ^h   Bacon, Philomena ⁱ   Olsen, Jan Abel ^j   Gyrd Hansen, Dorte ^d   Kjaer, Trine ^d   Beck, Mickael ^d   Nielsen, Jytte Seested ^d   Persson, Ulf ^k   Bergman, Annika ^k   Protière, Christel ^l   Moatti, JeanPaul ^l   Luchini, Stephane ^m   Prades, Jose Luis Pinto ^b   Mataria, Awad ⁿ   Khatib, Rana ⁿ   Jaralla, Yara ⁿ   Van Exel, Job ^c   Topór Madry, Roman ^o   Kozierkiewicz, Adam ^o   Poznanski, Darek ^o   Kocot, Ewa ^o   Gulácsi, László ^p   Péntek, Márta ^p   Kharroubi, Samer ^q   Manca, Andrea ^q   Shackley, Phil ^r   more..

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e Dansk Sundhedsinstitut   (Denmark)

^f UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h MONASH UNIVERSITY   (Australia)

ⁱ UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^j UNIVERSITY OF TROMSØ   (Norway)

^k SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^l AIX MARSEILLE UNIVERSITY   (France)

^m CNRS   (France)

ⁿ BIRZEIT UNIVERSITY   (Palestine)

^o JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^p Institute of Entrepreneurship and Innovation   (Hungary)

^q UNIVERSITY OF YORK   (United Kingdom)

^r UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

Contingent valuation; EuroVaQ; Willingness to pay

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DENMARK; FEMALE; FRANCE; HEALTH CARE COST; HUMAN; HUNGARY; LIFE EXPECTANCY; LIFE EXTENSION; LONGEVITY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NORWAY; POLAND; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; SOCIAL CLASS; SPAIN; UNITED KINGDOM; WILLINGNESS TO PAY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION MAKING; EUROPE; FINANCIAL MANAGEMENT; PATIENT ATTITUDE; PSYCHOLOGY; QUALITY OF LIFE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

COST-BENEFIT ANALYSIS; DECISION MAKING; EUROPE; FINANCING, PERSONAL; HUMANS; MODELS, ECONOMETRIC; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES;

EID: 84922265073     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.3018     Document Type: Article

References (44)

1. Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, et al. 2010. Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project. Health Technology Assessment 14(27).
2. Baker R, Chilton S, Donaldson C, Jones-Lee M, Lancsar E, Mason H et al. 2011. Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. Health Economics, Policy, and Law 6: 435.
3. Baron J, Greene J. 1996. Determinants of insensitivity to quantity in valuation of public goods: contribution, warm glow, budget constraints, availability, and prominence. Journal of Experimental Psychology: Applied 2(2): 107-125.
4. Barry M, Tilson L. 2007. Recent developments in pricing and reimbursement of medicines in Ireland. Expert Review of Pharmacoeconomics & Outcomes Research 7: 605-611.
5. Beattie J, Covey J, Dolan P, Hopkins L, Jones-Lee M, Loomes G et al. 1998. On the contingent valuation of safety and the safety of contingent valuation: Part 1 - caveat investigator. Journal of Risk and Uncertainty 17(1): 5-26.
6. Berry SR, Hubay S, Soibelman H, Martin DK. 2007. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study. BMC Health Services Research 7: 193.
7. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF. 2010. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value in Health 13: 1046-1055.
8. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF. 2012. Inquiry into the relationship between equity weights and the value of a QALY. Value in Health 15: 1119-1126.
9. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF. 2013. Valuing QALY gains applying a societal perspective. Health Economics 22: 1272-1281.
10. Brouwer WBF, Culyer AJ, Van Exel NJA, Rutten FFH. 2008. Welfarism vs. extra-welfarism. Journal of health economics 27(2): 325-338.
11. Cairns J. 1994. Valuing future health benefits. Health Economics 3: 221-229.
12. Carthy T, Chilton S, Covey J, Hopkins L, Jones-Lee M, Loomes G et al. 1999. On the contingent valuation of safety and the safety of contingent valuation: part 2 - the CV/SG "chained" approach. Journal of Risk and Uncertainty 17(3): 187-213.
13. Corens D. 2007. Belgium. In Health Systems in Transition. World Health Organisation and European Observatory of Health Systems and Policies: Copenhagen.
14. Culyer AJ, McCabe CJ, Briggs AH, Claxton K, Buxton M, Akehurst R et al. 2007. Searching for a threshold not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy 12: 56-8.
15. Dolan P, Gudex C, Kind P, Williams AA. 1999. Social Tariff for EuroQoL: Results from a UK General Population Survey. CHE Discussion Paper 138, York: Centre for Health Economics, University of York, UK.
16. Donaldson C, Atkinson A, Bond J, Wright I. 1988. Should QALYs be programme-specific? Journal of Health Economics 7: 239-257.
17. European Value of a Quality Adjusted Life Year, project no. SP5A-CT-2007-044172, 2010. http://research.ncl.ac.uk/eurovaq/EuroVaQ-Final-Publishable-Report-and-Appendices.pdf [16 June 2010].
18. Gyrd-Hansen D. 2003. Willingness to pay for a QALY. Health Economics 12: 1049-60.
19. Gyrd-Hansen D, Kjær T. 2012. Disentangling WTP per QALY data: different analytical approaches, different answers. Health Economics 21(3): 222-237.
20. Haninger K, Hammitt JK. 2011. Diminishing willingness to pay per Quality-Adjusted Life Year: valuing acute foodborne illness. Risk Analysis 31(9): 1363-1380.
21. Hirth RA, Chernew ME, Miller E, Fendrick MA, Weissert WG. 2000. Willingness to pay for a quality-adjusted life year: in search of a standard. Medical Decision Making 20: 332.
22. Johannesson M, Johansson P-O. 1997. Quality of life and the WTP for an increase in life expectancy at an advanced age. Journal of Public Economics 65: 219-228.
23. Jonsson B, Willking N. 2007. Market access for cancer drugs and the role of health economics. Annals of Oncology 18: 55-66.
24. Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA. 2011. How long and how well: oncologists' attitudes toward the relative value of life-prolonging v quality of life-enhancing treatments. Medical Decision Making 31: 380-385.
25. Lancsar E, Wildman J, Donaldson C, Ryan M, Baker R. 2011. Deriving distributional weights for QALYs through discrete choice experiments. Journal of Health Economics 30 (2): 466-478.
26. Mason H, Jones-Lee MW, Donaldson C. 2009. Modelling the monetary value of a QALY: a new approach based on UK data. Health Economics 18: 933.
27. Mason H, Baker RM, Donaldson C. 2009. Willingness to pay for a QALY: past, present and the future. Expert Reviews of Pharmacoeconomics and Outcomes Research 8(6): 575-582.
28. McCabe C, Claxton K, Culyer A. 2008. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics 26: 733-44.
29. National Institute for Health and Clinical Excellence. 2009. Appraising life-extending, end of life treatments. http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf [10 October 2012].
30. Ng ES-W, Grieve R, Carpenter JR. 2013. Two stage non-parametric bootstrap sampling with shrinkage correction for clustered data. Stata Journal 13(1): 141-164.
31. Nord E. 2005. Concerns for the worse off: fair innings vs severity. Social Science & Medicine 60(2): 257-263.
32. Olsen JA, Donaldson C. 1998. Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes. Social Science and Medicine 46: 1-12.
33. Palmer S, Raftery J. 1999. Economics notes: opportunity cost. BMJ British Medical Journal 318(7197): 1551.
34. Philipson TJ, Becker G, Goldman D, Murphy KM. 2010. Terminal care and the value of life near its end. Working Paper 15649, National Bureau of Economic Research, Cambridge, Mass. http://www.nber.org/papers/w15649 [25 August 2011].
35. Porat A, Tabbach AD. 2010. Risk of Death. University of Chicago Law and Economics Olin Working Paper No. 531. http://www.law.uchicago.edu/files/file/531-ap-death.pdf [22 September 2010]
36. Pratt JW, Zeckhauser RJ. 1996. Willingness to Pay and the distribution of risk and wealth. Journal of Political Economy 104(4): 747-763.
37. Raftery J. 2008. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Medical Journal of Australia 188: 26-28.
38. Robinson A, Gyrd-Hansen D, Bacon P, Baker R, Pennington M, Donaldson C, EuroVaQ Team. 2013. Estimating a WTP-based value of a QALY: the 'chained' approach. Social Science & Medicine 92: 92-104.
39. Schlander M. 2010. Measures of efficiency in healthcare: QALMs about QALYs? Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 104(3): 214-226.
40. Schwappach DLB. 2002. Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expectations 5: 210.
41. Shah KK. 2009. Severity of illness and priority setting in health care: a review of the literature. Health policy 93: 77-84.
42. Snyder CR. 1994. The Psychology of Hope. Free Press: New York.
43. Stewart JM, O'Shea E, Donaldson C, Shackley P. 2002. Do ordering effects matter in willingness-to-pay studies of health care?. Journal of health economics 21(4): 585-599.
44. Weinstein MC. 2008. How much are Americans willing to pay for a quality-adjusted life year? Medical Care 46(4):343